metformin has been researched along with Nervous System Disorders in 3 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin is a first-line drug for treating type 2 diabetes mellitus (T2DM) and one of the most commonly prescribed drugs in the world." | 2.82 | Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders. ( Fei, E; Li, N; Zhou, T, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Li, N | 1 |
| Zhou, T | 1 |
| Fei, E | 1 |
| Gantois, I | 1 |
| Popic, J | 1 |
| Khoutorsky, A | 1 |
| Sonenberg, N | 1 |
| Łabuzek, K | 1 |
| Gabryel, B | 1 |
| Okopień, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Prospective, Cohort Study to Elucidate the Effects of Metformin Treatment on Steroid Hormones and Social Behavior. Linking Autistic Behaviorial Symptoms to Changes in Steroid Hormone Availability[NCT04930471] | 45 participants (Anticipated) | Observational | 2021-06-30 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for metformin and Nervous System Disorders
| Article | Year |
|---|---|
Actions of Metformin in the Brain: A New Perspective of Metformin Treatments in Related Neurological Disorders.
Topics: Brain; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin | 2022 |
Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.
Topics: Animals; Autistic Disorder; Disease Models, Animal; Fragile X Mental Retardation Protein; Fragile X | 2019 |
[Metformin as a key to alternative activation of microglia?].
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents; Blood-Brain Barrier; Brain; Cells, | 2014 |